{"id":827462,"date":"2025-03-19T08:09:43","date_gmt":"2025-03-19T12:09:43","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-to-report-full-year-2024-financial-results-on-march-21-2025-and-host-conference-call-and-webcast\/"},"modified":"2025-03-19T08:09:43","modified_gmt":"2025-03-19T12:09:43","slug":"moleculin-to-report-full-year-2024-financial-results-on-march-21-2025-and-host-conference-call-and-webcast","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-to-report-full-year-2024-financial-results-on-march-21-2025-and-host-conference-call-and-webcast\/","title":{"rendered":"Moleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and Webcast"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">\n        <strong>HOUSTON, March  19, 2025  (GLOBE NEWSWIRE) &#8212; <\/strong><br \/>\n        <strong>Moleculin Biotech, Inc.<\/strong>, (Nasdaq: MBRX) (\u201cMoleculin\u201d or the \u201cCompany\u201d), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced that it will report its financial results for the year ended December 31, 2024, on Friday afternoon, March 21, 2025. Moleculin management will host a conference call and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=fj-IqPBqemdZPiOiJLQgXhUqRI4PaLGHj0TwFxDQ_4Gh0KgXklM-lyR3S1j_dRPF3P1VkeSE-mTa2nsf2WUKEtczILzSteIeVpwR431t8qjSsWHcbop5L4sFazyrP8adRhH4kzMnnDNzwakUYVqRvw9fJSyEfQUtcphWi0cgXIU=\" rel=\"nofollow\" target=\"_blank\">live audio webcast\u00a0<\/a>to discuss the operational and financial results on Monday morning, March 24, 2025 at 8:30 AM ET.<\/p>\n<p align=\"justify\">Interested participants and investors may access the conference call by dialing (877) 407-0832 (domestic) or (201) 689-8433 (international) and referencing the Moleculin Biotech Conference Call. The\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=fj-IqPBqemdZPiOiJLQgXhUqRI4PaLGHj0TwFxDQ_4EKj6qyEgDBKuQlTkd6aQES2ENBMvOSDPD9vtlsYslzoVf8lULB1BXac8zx0K_qWIWgeZBSx9J3nfbjLCQwEllNlj3c8O5wAhY7zxdRrz6KlYIynEavidRwNp_b1Mi02V4=\" rel=\"nofollow\" target=\"_blank\">live audio webcast\u00a0<\/a>will be accessible on the\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=y_Xs-hk9yv1n-x4DyXMZvaD5WgSxUSGlXMSx0Oaz07XPFhXpYt6_e870wZPFWSKmK6yVGd6nfIIATR36O0ARxQ==\" rel=\"nofollow\" target=\"_blank\">Events<\/a>\u00a0page of the\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=p5DYx_1CJi70YnlE2pc00xHUmDF6ssPOJeSDTjI9n6vXDAA2pfBJl3TLZEoQrg294pSFPDkzmbSMKu7FH7Dh0JtaXZD2bFmnGoZkQeB85xQ=\" rel=\"nofollow\" target=\"_blank\">Investors<\/a>\u00a0section of the Moleculin website,\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=uyq0hWf_lA0doTnUCaZZc1gIkDPrxaA8QrQLygzpSXTAV9qdfI2IHgFs3vDfGopLinpUKw7W0BSyhjwaI32FrA==\" rel=\"nofollow\" target=\"_blank\">moleculin.com<\/a>, and will be archived for 90 days.<\/p>\n<p>\n        <strong>About Moleculin Biotech, Inc.<\/strong>\n      <\/p>\n<p align=\"justify\">Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company\u2019s lead program, Annamycin, is a next-generation anthracycline designed to avoid multidrug resistance mechanisms and to eliminate the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.<\/p>\n<p align=\"justify\">The Company is initiating the MIRACLE (<strong>M<\/strong>olecul<strong>i<\/strong>n <strong>R<\/strong>\/R AML <strong>A<\/strong>nnAraC <strong>Cl<\/strong>inical <strong>E<\/strong>valuation) Trial (MB-108), a pivotal, adaptive design Phase 3 trial evaluating Annamycin in combination with cytarabine, together referred to as AnnAraC, for the treatment of relapsed or refractory acute myeloid leukemia. Following a successful Phase 1B\/2 study (MB-106), with input from the FDA, the Company believes it has substantially de-risked the development pathway towards a potential approval for Annamycin for the treatment of AML. This study is subject to appropriate future filings with potential additional feedback from the FDA and their foreign equivalents.<\/p>\n<p align=\"justify\">Additionally, the Company is developing WP1066, an Immune\/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin is also engaged in the development of a portfolio of antimetabolites, including WP1122 for the potential treatment of pathogenic viruses, as well as certain cancer indications.<\/p>\n<p align=\"justify\">For more information about the Company, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=iZcA3yESNvoYR3QTi5kSI99LJO-9bBVXSdVpB4U9HvISktpyg6E0__rQDVo1V2S_bZDdd6cEbhVSLjr25sM13FI0mEEHW__7e1rkMKthI-Q=\" rel=\"nofollow\" target=\"_blank\">www.moleculin.com<\/a> and connect on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_diQ24fOj9jV_4LzOPfaQC5imuYlyp5TrrkDyj6cefrBAlOK9ppOsnXNPkeSmMdAzSw_iaugaheNOx7kxcdvcA==\" rel=\"nofollow\" target=\"_blank\">X<\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xh3c-yXR8ZD-0p9MqvI1lVnIIU05FHnmEsL_Y2UBiy5NQru08z49xUBh5jTn9wbQfPk1yOPK8Q_EyBr-bQVvxWEdoJRb0RLCq8OUKPeOL6oHCrybm6I7gI7xq1zL8Yhh\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=UG8q6tHYGAWDiZadvUNXFjtbmw2g9RmiJpzBSooU5WZhOIempZQXVOqlwhKNiRC2xZ74SfV5PmF5NSg8MrF2teg3JP2o66VNR-XI7h7HEDg=\" rel=\"nofollow\" target=\"_blank\">Facebook<\/a>.<\/p>\n<p>\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>JTC Team, LLC<br \/>Jenene Thomas<br \/>(908) 824-0775<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=fPXjc9fTWhLoDo8kFnU05b1-s6ntji6bRU_eZyj8rCIAyskUMRP85AFaAxZp2A_q1rBnmp2rLZFcqasaO5dtng==\" rel=\"nofollow\" target=\"_blank\">MBRX@jtcir.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5Njc4OSM2ODEyODIyIzUwMDEzMzYwNw==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NjljNTE3ZmMtMWYyMi00M2FhLWE2NDMtZTkxMzg0YTkwOTkxLTUwMDEzMzYwNy0yMDI1LTAzLTE5LWVu\/tiny\/Moleculin-Biotech-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>HOUSTON, March 19, 2025 (GLOBE NEWSWIRE) &#8212; Moleculin Biotech, Inc., (Nasdaq: MBRX) (\u201cMoleculin\u201d or the \u201cCompany\u201d), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced that it will report its financial results for the year ended December 31, 2024, on Friday afternoon, March 21, 2025. Moleculin management will host a conference call and live audio webcast\u00a0to discuss the operational and financial results on Monday morning, March 24, 2025 at 8:30 AM ET. Interested participants and investors may access the conference call by dialing (877) 407-0832 (domestic) or (201) 689-8433 (international) and referencing the Moleculin Biotech Conference Call. The\u00a0live audio webcast\u00a0will be accessible on the\u00a0Events\u00a0page of the\u00a0Investors\u00a0section of the Moleculin website,\u00a0moleculin.com, and &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-to-report-full-year-2024-financial-results-on-march-21-2025-and-host-conference-call-and-webcast\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Moleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and Webcast&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-827462","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Moleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and Webcast - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-to-report-full-year-2024-financial-results-on-march-21-2025-and-host-conference-call-and-webcast\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Moleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and Webcast - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"HOUSTON, March 19, 2025 (GLOBE NEWSWIRE) &#8212; Moleculin Biotech, Inc., (Nasdaq: MBRX) (\u201cMoleculin\u201d or the \u201cCompany\u201d), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced that it will report its financial results for the year ended December 31, 2024, on Friday afternoon, March 21, 2025. Moleculin management will host a conference call and live audio webcast\u00a0to discuss the operational and financial results on Monday morning, March 24, 2025 at 8:30 AM ET. Interested participants and investors may access the conference call by dialing (877) 407-0832 (domestic) or (201) 689-8433 (international) and referencing the Moleculin Biotech Conference Call. The\u00a0live audio webcast\u00a0will be accessible on the\u00a0Events\u00a0page of the\u00a0Investors\u00a0section of the Moleculin website,\u00a0moleculin.com, and &hellip; Continue reading &quot;Moleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and Webcast&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-to-report-full-year-2024-financial-results-on-march-21-2025-and-host-conference-call-and-webcast\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-19T12:09:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5Njc4OSM2ODEyODIyIzUwMDEzMzYwNw==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moleculin-to-report-full-year-2024-financial-results-on-march-21-2025-and-host-conference-call-and-webcast\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moleculin-to-report-full-year-2024-financial-results-on-march-21-2025-and-host-conference-call-and-webcast\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Moleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and Webcast\",\"datePublished\":\"2025-03-19T12:09:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moleculin-to-report-full-year-2024-financial-results-on-march-21-2025-and-host-conference-call-and-webcast\\\/\"},\"wordCount\":394,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moleculin-to-report-full-year-2024-financial-results-on-march-21-2025-and-host-conference-call-and-webcast\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5Njc4OSM2ODEyODIyIzUwMDEzMzYwNw==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moleculin-to-report-full-year-2024-financial-results-on-march-21-2025-and-host-conference-call-and-webcast\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moleculin-to-report-full-year-2024-financial-results-on-march-21-2025-and-host-conference-call-and-webcast\\\/\",\"name\":\"Moleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and Webcast - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moleculin-to-report-full-year-2024-financial-results-on-march-21-2025-and-host-conference-call-and-webcast\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moleculin-to-report-full-year-2024-financial-results-on-march-21-2025-and-host-conference-call-and-webcast\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5Njc4OSM2ODEyODIyIzUwMDEzMzYwNw==\",\"datePublished\":\"2025-03-19T12:09:43+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moleculin-to-report-full-year-2024-financial-results-on-march-21-2025-and-host-conference-call-and-webcast\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moleculin-to-report-full-year-2024-financial-results-on-march-21-2025-and-host-conference-call-and-webcast\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moleculin-to-report-full-year-2024-financial-results-on-march-21-2025-and-host-conference-call-and-webcast\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5Njc4OSM2ODEyODIyIzUwMDEzMzYwNw==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5Njc4OSM2ODEyODIyIzUwMDEzMzYwNw==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moleculin-to-report-full-year-2024-financial-results-on-march-21-2025-and-host-conference-call-and-webcast\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Moleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and Webcast\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Moleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and Webcast - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-to-report-full-year-2024-financial-results-on-march-21-2025-and-host-conference-call-and-webcast\/","og_locale":"en_US","og_type":"article","og_title":"Moleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and Webcast - Market Newsdesk","og_description":"HOUSTON, March 19, 2025 (GLOBE NEWSWIRE) &#8212; Moleculin Biotech, Inc., (Nasdaq: MBRX) (\u201cMoleculin\u201d or the \u201cCompany\u201d), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced that it will report its financial results for the year ended December 31, 2024, on Friday afternoon, March 21, 2025. Moleculin management will host a conference call and live audio webcast\u00a0to discuss the operational and financial results on Monday morning, March 24, 2025 at 8:30 AM ET. Interested participants and investors may access the conference call by dialing (877) 407-0832 (domestic) or (201) 689-8433 (international) and referencing the Moleculin Biotech Conference Call. The\u00a0live audio webcast\u00a0will be accessible on the\u00a0Events\u00a0page of the\u00a0Investors\u00a0section of the Moleculin website,\u00a0moleculin.com, and &hellip; Continue reading \"Moleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and Webcast\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-to-report-full-year-2024-financial-results-on-march-21-2025-and-host-conference-call-and-webcast\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-19T12:09:43+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5Njc4OSM2ODEyODIyIzUwMDEzMzYwNw==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-to-report-full-year-2024-financial-results-on-march-21-2025-and-host-conference-call-and-webcast\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-to-report-full-year-2024-financial-results-on-march-21-2025-and-host-conference-call-and-webcast\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Moleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and Webcast","datePublished":"2025-03-19T12:09:43+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-to-report-full-year-2024-financial-results-on-march-21-2025-and-host-conference-call-and-webcast\/"},"wordCount":394,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-to-report-full-year-2024-financial-results-on-march-21-2025-and-host-conference-call-and-webcast\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5Njc4OSM2ODEyODIyIzUwMDEzMzYwNw==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-to-report-full-year-2024-financial-results-on-march-21-2025-and-host-conference-call-and-webcast\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-to-report-full-year-2024-financial-results-on-march-21-2025-and-host-conference-call-and-webcast\/","name":"Moleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and Webcast - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-to-report-full-year-2024-financial-results-on-march-21-2025-and-host-conference-call-and-webcast\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-to-report-full-year-2024-financial-results-on-march-21-2025-and-host-conference-call-and-webcast\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5Njc4OSM2ODEyODIyIzUwMDEzMzYwNw==","datePublished":"2025-03-19T12:09:43+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-to-report-full-year-2024-financial-results-on-march-21-2025-and-host-conference-call-and-webcast\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-to-report-full-year-2024-financial-results-on-march-21-2025-and-host-conference-call-and-webcast\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-to-report-full-year-2024-financial-results-on-march-21-2025-and-host-conference-call-and-webcast\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5Njc4OSM2ODEyODIyIzUwMDEzMzYwNw==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5Njc4OSM2ODEyODIyIzUwMDEzMzYwNw=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-to-report-full-year-2024-financial-results-on-march-21-2025-and-host-conference-call-and-webcast\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Moleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and Webcast"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/827462","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=827462"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/827462\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=827462"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=827462"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=827462"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}